,Unnamed: 0,index,Rank,NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL,arms,arm1,arm2,arm1_included,arm2_included,arm1_to_remove,arm2_to_remove,new_arm1,new_arm2,also_arm1_to_remove,also_arm2_to_remove,arm1_has_approved_drugs,arm2_has_approved_drugs,Included,Reason
2,20,113,114,NCT00950365,Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC),,Unknown status,No Results Available,Non-small Cell Lung Cancer,Drug: Pemetrexed|Drug: pemetrexed and erlotinib,Progression-free survival|Objective response rate|Disease control rate|Safety profile of pemetrexed and erlotinib combination|Assessment of molecular markers for biologic effects and predictive response,Montefiore Medical Center|Eli Lilly and Company|OSI Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",Phase 2,82,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Pemetrexed/Erlotinib,6-May,11-May,,31-Jul-09,,31-Jul-09,"University of Massachusetts, Worcester, Massachusetts, United States|Albert Einstein Cancer Center, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT00950365,2.0,pemetrexed,pemetrexed and erlotinib,1,1,False,False,pemetrexed,pemetrexed and erlotinib,False,False,1.0,1.0,TRUE,
4,52,225,226,NCT00702182,Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer,,Completed,No Results Available,Non-Small Cell Lung Cancer,Drug: Vinorelbine (Navelbine)|Drug: Erlotinib,Define the recommended dose of oral navelbine with erlotinib,"National Cancer Centre, Singapore",All,"21 Years and older   (Adult, Older Adult)",Phase 1,30,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EPCTG-VEP1,8-Apr,12-Apr,12-Oct,20-Jun-08,,19-Oct-12,"National Cancer Center Singapore, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT00702182,2.0,vinorelbine (navelbine),erlotinib,1,1,False,False,vinorelbine (navelbine),erlotinib,False,False,1.0,1.0,TRUE,
5,56,230,231,NCT00440414,Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC),,Completed,No Results Available,Non Small Cell Lung Cancer,Drug: Erlotinib (Tarceva)|Drug: Pemetrexed (Alimta),Time to Tumor Progression|Overall response rate|Overall survival between the two treatment arms|Quality of life assessment|Toxicity profile between the two treatment arms,Hellenic Oncology Research Group|University Hospital of Crete,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 3,320,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CT/06.05,6-Apr,10-Apr,10-Apr,27-Feb-07,,19-Aug-10,"University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece|401 Military Hospital, Medical Oncology Unit, Athens, Greece|Air Forces Military Hospital, Dep of Medical Oncology, Athens, Greece|IASO General Hospital of Athens, 1st Department of Medical Oncology, Athens, Greece|Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece|Sismanogleio General Hospital, 1st, 2nd Department of Pulmonary Diseases, Athens, Greece|Sotiria General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases, Athens, Greece|Metaxa's Anticancer Hospital of Piraeus,1st Dep of Medical Oncology, Piraeus, Greece|Theagenion Anticancer Hospital of Thessaloniki, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT00440414,2.0,erlotinib (tarceva),pemetrexed (alimta),1,1,False,False,erlotinib (tarceva),pemetrexed (alimta),False,False,1.0,1.0,TRUE,
8,86,368,369,NCT00908336,Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen,,Unknown status,No Results Available,Non-Small Cell Lung Cancer,Drug: Docetaxel and Erlotinib|Drug: Erlotinib,Percentage of patients without disease progression after 6 months of treatment.|Progression-free survival|Duration of Response|Overall Response Rate|Disease Control Rate|Overall survival|Safety profile,Hospital Arnau de Vilanova,All,"18 Years and older   (Adult, Older Adult)",Phase 2,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML25033,9-Mar,10-Aug,10-Dec,25-May-09,,25-May-09,"Hospital Virgen de los Lirios, Alcoy, Alicante, Spain|Hospital Clínica de Benidorm, Benidorm, Alicante, Spain|Hospital General de Elda, Elda, Alicante, Spain|Hospital Provincial de Castellón, Castellón de la Plana, Castellón, Spain|Hospital de Sagunto, Sagunto, Valencia, Spain|Hospital San Juan de Alicante, Alicante, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain",,https://ClinicalTrials.gov/show/NCT00908336,2.0,docetaxel and erlotinib,erlotinib,1,1,False,False,docetaxel and erlotinib,erlotinib,False,False,1.0,1.0,TRUE,
10,134,509,510,NCT01196078,A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer,,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: erlotinib [Tarceva]|Drug: vinorelbine,Percentage of Participants Achieving a Best Overall Response of Complete Response (CR) or Partial Response (PR)|Percentage of Participants Achieving Disease Control|Duration of Response Among Participants Who Achieved Either a CR or PR|Percentage of Participants With Disease Progression|Time to Disease Progression|Overall Survival: Percentage of Participants With an Progressive Disease or Death|Overall Survival: Time to Event|Quality of Life as Measured by the Functional Assessment of Cancer Therapy (FACT) Questionnaire|Changes in Quality of Life as Measured by the FACT Questionnaire|Percentage of Participants With Changes in Quality of Life as Measured by FACT Questionnaire Scores by Category of Change|Changes in Quality of Life as Assessed by FACT-L (Lung Symptoms) Questionnaire|Percentage of Participants With Changes in FACT-L (Lung Symptoms) by Category of Change,Hoffmann-La Roche,All,70 Years and older   (Older Adult),Phase 4,114,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML20322,7-Feb,10-Dec,10-Dec,8-Sep-10,27-Jul-15,27-Jul-15,"Taipei, Taiwan",,https://ClinicalTrials.gov/show/NCT01196078,2.0,erlotinib [tarceva],vinorelbine,1,1,False,False,erlotinib [tarceva],vinorelbine,False,False,1.0,1.0,TRUE,
11,139,553,554,NCT01350817,Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer,TARSEQ,Completed,No Results Available,Non Small Cell Lung Cancer,Drug: Erlotinib + docetaxel|Drug: Docetaxel,Progression free survival at 15 weeks.|Free survival at 12 months|Toxicities and feasibility,"University Hospital, Limoges|Hoffmann-La Roche",All,"18 Years and older   (Adult, Older Adult)",Phase 2,156,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,I10004,11-May,13-Mar,14-Jan,10-May-11,,3-Apr-15,"Service de Pneumologie, CHU Angers, Angers, France|Service de pneumologie; Centre Hospitalier d'Annecy, Annecy, France|Service de Pneumologie; Centre Hospitalier, Beauvais, France|Service de Pneumologie, Beauvais, France|Service de Pneumologie, Bordeaux, France|CHU Brest, Brest, France|Service de Pneumologie, Charleville Mezière, France|Service de Pneumologie ; Centre hospitalier, Charleville-Mezieres, France|Service de Pneumologie, Créteil, France|Service de Pneumologie; Centre Hospitalier, Draguignan, France|Service de Pneumologie, Draguignan, France|Service de Pneumologie, Elbeuf, France|Service de Pneumologie, Gap, France|Département de Pathologie Respiratoire du CHU de Limoges, Limoges, France|Service de Pneumologie, Hôpital de la Croix Rousse, Lyon, France|Service de Pneumologie-Neurologie ; Centre Hospitalier F. Quesnay, Mantes La Jolie, France|Département des Maladies Respiratoires ; Hôpital Sainte Marguerite, Marseille, France|CH de Meaux, Meaux, France|Service de Pneumologie, Meaux, France|Service de Pneumologie, Mulhouse, France|Service de Pneumologie - Hôpital St Antoine, Paris, Paris, France|Service de Pneumologie-Allergologie; Centre Hospitalier Général, Perigueux, France|CHU Reims, Reims, France|Service de Pneumologie, Hôpital Pontchailloux, Rennes, France|Service de Pneumologie; CHG de Roanne, Roanne, France|Clinique Pneumologique; Hôpital Charles Nicolle, Rouen, France|Service de Pneumologie; Hôpital Bois Guillaume, Rouen, France|Hôpital Charles Nicolle, Service de Pneumologie, Rouen, France|Service de Pneumologie, Hôpital Nord, saint Etienne, France|Service de Pneumologie, Villefranche, France",,https://ClinicalTrials.gov/show/NCT01350817,2.0,erlotinib + docetaxel,docetaxel,1,1,False,False,erlotinib + docetaxel,docetaxel,False,False,1.0,1.0,TRUE,
12,153,601,602,NCT00976456,Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer,65plus,Completed,Has Results,Non-squamous Non-small Cell Lung Cancer,Drug: Bevacizumab + Pemetrexed|Drug: Bevacizumab + Pemetrexed + Carboplatin,Progression Free Survival|Overall Survival,PD Dr. med. Wolfgang Schuette|Roche Pharma AG|Eli Lilly and Company|Martha-Maria Krankenhaus Halle-Dölau gGmbH,All,65 Years and older   (Older Adult),Phase 3,271,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,65 plus|ML21896,9-Sep,14-Oct,14-Oct,14-Sep-09,10-Mar-16,10-Mar-16,"Krankenhaus Martha-Maria Halle-Doelau, Halle, Germany",,https://ClinicalTrials.gov/show/NCT00976456,2.0,bevacizumab + pemetrexed,bevacizumab + pemetrexed + carboplatin,1,1,False,False,bevacizumab + pemetrexed,bevacizumab + pemetrexed + carboplatin,False,False,1.0,1.0,TRUE,
14,156,622,623,NCT00678964,Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC),TIE,Unknown status,No Results Available,Non-Small Cell Lung Cancer,Drug: Erlotinib|Drug: Vinorelbine and Carboplatin,"Evaluation of the progression free survival rate with the first-line therapy|Duration of remission|1-year survival|Overall survival|Response rate (CR/RR)|Quality of life, improvement of symptoms (FACT-L)|Simplified Charlsons´Comorbidity Score|Safety and Tolerability",LungenClinic Grosshansdorf,All,70 Years and older   (Older Adult),Phase 2,260,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EudraCT 2005-005827-32|ML19747,6-Jun,8-Nov,,16-May-08,,16-May-08,"Gemeinschaftspraxis, Augsburg, Germany|Zentralklinik Bad Berka GmbH, Bad Berka, Germany|Charité - Campus Benjamin Franklin, Berlin, Germany|Helios Klinikum Emil von Behring, Berlin, Germany|Evangelische Lungenklinik Berlin, Berlin, Germany|Evang. Krankenhaus Bielefeld, Bielefeld, Germany|Johanniter-Krankenhaus Bonn, Bonn, Germany|Gemeinschaftspraxis, Celle, Germany|Fachkrankenhaus Coswig, Coswig, Germany|Fachklinik Diekholzen, Diekholzen, Germany|Klinikum Donaustauf, Donaustauf, Germany|Katholisches Klinikum Duisburg, Duisburg, Germany|Marien Hospital Düsseldorf, Düsseldorf, Germany|Universitätsklinik Essen, Essen, Germany|Klinikum Essen-Mitte, Essen, Germany|Krankenhaus Nordwest GmbH, Frankfurt/Main, Germany|Asklepios Fachkliniken München-Gauting, Gauting, Germany|Schwerpunktpraxis Onkologie, Goslar, Germany|Universitätsklinikum der Ernst-Moritz Arndt Universität Greifswald, Greifswald, Germany|Krankenhaus Großhansdorf, Großhansdorf, Germany|Georg-August-Universität Göttingen, Göttingen, Germany|Allgemeines Krankenhaus Harburg, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany|Lungenklinik Hemer, Hemer, Germany|Universitätsklinik des Saarlandes, Homburg/Saar, Germany|Klinikum der Friedrich-Schiller-Universität, Jena, Germany|Klinikum Kassel, Kassel, Germany|Malteser Krankenhaus St. Hildegardis Köln, Köln, Germany|Klinikum Leverkusen gGmbH, Leverkusen, Germany|Klinik Löwenstein gGmbH, Loewenstein, Germany|Universitätsklinikum Schleswig-Holstein, Lübeck, Germany|Katholisches Klinikum Mainz, Mainz, Germany|Klinikum der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Mannheim gGmbH, Mannheim, Germany|Zweckverband Kliniken im Mühlenkreis, Minden, Germany|Medizinische Klinik - Innenstadt, München, Germany|Ruppiner Kliniken GmbH, Neuruppin, Germany|Johanniter-Krankenhaus im Fläming gGmbH, Treuenbrietzen, Germany|Universitätsklinikum Ulm, Ulm, Germany",,https://ClinicalTrials.gov/show/NCT00678964,2.0,erlotinib,vinorelbine and carboplatin,1,1,False,False,erlotinib,vinorelbine and carboplatin,False,False,1.0,1.0,TRUE,
16,177,699,700,NCT00940875,A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer,,Terminated,Has Results,Non-Small Cell Lung Cancer,Drug: erlotinib [Tarceva]|Drug: gemcitabine,Percentage of Participants With Disease Progression or Death|PFS|Percentage of Participants Who Achieved Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST V 1.0|Percentage of Participants With Non-Progression at Weeks 8 and 16|Percentage of Participants Who Died|Overall Survival (OS)|Duration of Response,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,54,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML22429,9-Jun,11-Sep,11-Sep,16-Jul-09,2-Apr-15,2-Apr-15,"Port Macquarie, New South Wales, Australia|Randwick, New South Wales, Australia|Sydney, New South Wales, Australia|Sydney, New South Wales, Australia|Tweed Heads, New South Wales, Australia|Wollongong, New South Wales, Australia|Brisbane, Queensland, Australia|Greenslopes, Queensland, Australia|Woolloongabba, Queensland, Australia|Richmond, South Australia, Australia|Terrace Gardens, South Australia, Australia|Hobart, Tasmania, Australia|Bendigo, Victoria, Australia|Heidelberg, Victoria, Australia|Melbourne, Victoria, Australia|Wodonga, Victoria, Australia|Fremantle, Western Australia, Australia",,https://ClinicalTrials.gov/show/NCT00940875,2.0,erlotinib [tarceva],gemcitabine,1,1,False,False,erlotinib [tarceva],gemcitabine,False,False,1.0,1.0,TRUE,
18,183,731,732,NCT00700180,A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.,,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: bevacizumab [Avastin]|Drug: Carboplatin-based chemotherapy,"Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) by Dichotomized Baseline Plasma Marker Level|Progression-Free Survival - Percentage of Participants With an Event|Progression-Free Survival - Time to Event|Percentage of Participants With Objective Response|Percentage of Participants With Measurable Disease at Baseline Who Achieved CR, PR, or Stable Disease (SD) for at Least 6 Weeks|Duration of Response - Percentage of Participants With an Event|Duration of Response - Time to Event|Overall Survival - Percentage of Participants With an Event|Overall Survival - Time to Event",Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,303,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BO21015|2008-000662-23,8-Sep,12-Sep,12-Sep,18-Jun-08,25-Sep-14,25-Sep-14,"St. Leonards, New South Wales, Australia|Adelaide, South Australia, Australia|Adelaide, South Australia, Australia|Box Hill, Victoria, Australia|Fitzroy, Victoria, Australia|Antwerpen, Belgium|Liege, Belgium|Vancouver, British Columbia, Canada|Toronto, Ontario, Canada|Ostrava, Czech Republic|Praha, Czech Republic|Odense, Denmark|Paris, France|Rouen, France|Bad Berka, Germany|Grosshansdorf, Germany|Hamburg, Germany|Oldenburg, Germany|Hong Kong, Hong Kong|Hong Kong, Hong Kong|Budapest, Hungary|Edeleny, Hungary|Sopron, Hungary|Szombathely, Hungary|Torokbalint, Hungary|Milano, Italy|Milan, Italy|Orbassano, Italy|Roma, Italy|Den Haag, Netherlands|Enschede, Netherlands|Hoorn, Netherlands|Nieuwegein, Netherlands|Rotterdam, Netherlands|Poznan, Poland|Warszawa, Poland|Zabrze, Poland|Arkhangelsk, Russian Federation|Chelyabinsk, Russian Federation|Kazan, Russian Federation|Kazan, Russian Federation|Krasnodar, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Saint-Petersburg, Russian Federation|St Petersburg, Russian Federation|Barakaldo, Vizcaya, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Changhua, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Aberdeen, United Kingdom|Chelmsford, United Kingdom|London, United Kingdom",,https://ClinicalTrials.gov/show/NCT00700180,2.0,bevacizumab [avastin],carboplatin-based chemotherapy,1,1,False,False,bevacizumab [avastin],carboplatin-based chemotherapy,False,False,1.0,1.0,TRUE,
19,185,737,738,NCT00891579,Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations,,Completed,No Results Available,Non Small Cell Lung Cancer,Drug: Pemetrexed (Alimta)|Drug: Gefitinib (IRESSA),Progression free survival (PFS)|Response rate (RR)|Overall survival (OS),Chinese Society of Lung Cancer,All,"18 Years to 80 Years   (Adult, Older Adult)",Phase 2,161,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,C-TONG0806,9-Feb,12-Sep,12-Nov,1-May-09,,10-Dec-12,"Lung Cancer Research Institute & Cancer Center of Guangdong General Hospital, Guangzhou, Guangdong, China|307 hospital of People's Liberation Army, Beijing, China|Peking Union Hospital, Beijing, China|Jilin Tumor Hospital, Changchun, China|Nanjing General Hospital of Nanjing Military Command, Nanjing, China|Shanghai Chest Hospital, Shanghai, China|The first hospital of China medical university, Shenyang, China",,https://ClinicalTrials.gov/show/NCT00891579,2.0,pemetrexed (alimta),gefitinib (iressa),1,1,False,False,pemetrexed (alimta),gefitinib (iressa),False,False,1.0,1.0,TRUE,
20,186,743,744,NCT00425191,Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.,,Completed,No Results Available,Non-small Cell Lung Cancer,Drug: Docetaxel and Gemcitabine|Drug: Gemcitabine cisplatin followed by docetaxel,Response Rate|Time to progression.,Sanofi,All,"18 Years to 70 Years   (Adult, Older Adult)",Phase 2,165,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,XRP6976B_2501,2-Jul,5-Apr,,22-Jan-07,,7-Dec-09,"Sanofi-Aventis, Milan, Italy",,https://ClinicalTrials.gov/show/NCT00425191,2.0,docetaxel and gemcitabine,gemcitabine cisplatin followed by docetaxel,1,1,False,False,docetaxel and gemcitabine,gemcitabine cisplatin followed by docetaxel,False,False,1.0,1.0,TRUE,
21,189,749,750,NCT00191191,To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC),,Completed,Has Results,Non-small Cell Lung Cancer,Drug: Pemetrexed 500 mg/m2|Drug: Pemetrexed 1000 mg/m2,Best Overall Response|Duration of Response|Progression-Free Survival (PFS)|Change From Baseline to 3 Months in Quality of Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL-ACD)|Change From Baseline to 3 Months in Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) Lung Cancer Subscale (LCS),Eli Lilly and Company,All,"20 Years to 75 Years   (Adult, Older Adult)",Phase 2,226,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,5250|H3E-JE-NS01,4-Oct,8-Oct,8-Oct,19-Sep-05,25-Nov-09,9-Dec-09,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ehime, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Gifu, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Gunma, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Hokkaido, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Kumamoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Miyagi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Niigata, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Okayama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Saitama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT00191191,2.0,pemetrexed 500 mg/m2,pemetrexed 1000 mg/m2,1,1,False,False,pemetrexed 500 mg/m2,pemetrexed 1000 mg/m2,False,False,1.0,1.0,TRUE,
22,191,751,752,NCT00556322,"A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)",,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: Alimta or Taxotere|Drug: erlotinib [Tarceva],Percentage of Participants Who Died (All Participants; Data Cutoff: 07 September 2010)|Duration of Overall Survival in All Participants (Data Cutoff 07 September 2010)|Probable Percentage of Participants Remaining Alive at 1 Year|Percentage of Participants Who Died in Epidermal Growth Factor Receptor (EGFR) Positive and Negative Population|Duration of OS in EGFR Positive and Negative Population|Probable Percentage of Participants Remaining Alive at 1 Year in the EGFR Positive and Negative Population|Percentage of Participants With Disease Progression or Death (All Participants; Data Cut Off 07 September 2010)|Progression-Free Survival (PFS) in All Participants (Data Cutoff 07 September 2010)|Probable Percentage of Participants Remaining Alive and Progression Free at 6 Months|Percentage of Participants With Disease Progression or Death in EGFR Positive and Negative Population (Data Cut Off 07 September 2010)|PFS in EGFR Positive and Negative Population (Data Cutoff 07 September 2010)|Probable Percentage of Participants Remaining Alive and Progression Free at 6 Months in EGFR Positive and Negative Population|Percentage of Participants Achieving a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) as Assessed by the Investigator Using RECIST|Percentage of Participants With Deterioration in Quality of Life Determined Using Functional Assessment of Cancer Therapy - Lung (FACT-L)|Time to Deterioration in Quality of Life Using FACT-L|Probable Percentage of Participants Remaining Without Deterioration in Quality of Life at 6 Months as Assessed by FACT-L|Percentage of Participants With Symptomatic Progression Using FACT-L|Time to Symptomatic Progression Using FACT-L|Probable Percentage of Participants With Symptomatic Progression at 6 Months as Assessed by FACT-L|Percentage of Participants With Deterioration in the Trial Outcome Index (TOI)|Time to Deterioration in the TOI|Probable Percentage of Participants With Deterioration in the TOI at 6 Months as Assessed by FACT-L,Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 3,424,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,BO18602,6-Mar,12-Jun,12-Jun,12-Nov-07,23-Feb-15,23-Feb-15,"St. Leonards, New South Wales, Australia|Waratah, New South Wales, Australia|Adelaide, South Australia, Australia|East Bentleigh, Victoria, Australia|Fitzroy, Victoria, Australia|Geelong, Victoria, Australia|Melbourne, Victoria, Australia|Innsbruck, Austria|Klagenfurt, Austria|Wien, Austria|Wien, Austria|Antwerpen, Belgium|Winnipeg, Manitoba, Canada|Oshawa, Ontario, Canada|Sault Ste Marie, Ontario, Canada|Toronto, Ontario, Canada|Laval, Quebec, Canada|Montreal, Quebec, Canada|Santiago, Chile|Beijing, China|Guangzhou, China|Guangzhou, China|Shanghai, China|Ceské Budejovice, Czech Republic|Olomouc, Czech Republic|Plzen, Czech Republic|Herlev, Denmark|Odense, Denmark|Bayonne, France|Brest, France|Clermont-ferrand, France|Dijon, France|Le Mans, France|Lille, France|Limoges, France|Paris, France|PAU, France|Toulouse, France|Vandoeuvre-les-nancy, France|Bad Berka, Germany|Bochum, Germany|Halle (Saale), Germany|Herne, Germany|Neuruppin, Germany|Villingen-Schwenningen, Germany|Athens, Greece|Athens, Greece|Heraklion, Greece|Budapest, Hungary|Budapest, Hungary|Deszk, Hungary|Nyíregyháza, Hungary|Pecs, Hungary|Szombathely, Hungary|Torokbalint, Hungary|Bologna, Emilia-Romagna, Italy|Roma, Lazio, Italy|Ancona, Marche, Italy|Daegu, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Kaunas, Lithuania|Klaipeda, Lithuania|Vilnius, Lithuania|Kuala Lumpur, Malaysia|Penang, Malaysia|Auckland, New Zealand|Christchurch, New Zealand|Lodz, Poland|Lodz, Poland|Otwock, Poland|Bucuresti, Romania|Cluj Napoca, Romania|Iasi, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Balashikha, Russian Federation|Chelyabinsk, Russian Federation|Kazan, Russian Federation|Kazan, Russian Federation|Kirov, Russian Federation|Krasnodar, Russian Federation|Krasnodar, Russian Federation|Kuzmolovo, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Perm, Russian Federation|Smolensk, Russian Federation|Soshi, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|Yaroslavl, Russian Federation|Banska Bystrica, Slovakia|Bratislava, Slovakia|Nitra, Slovakia|Poprad, Slovakia|Golnik, Slovenia|Ljubljana, Slovenia|Maribor, Slovenia|Durban, South Africa|Johannesburg, South Africa|Pretoria, South Africa|Oviedo, Asturias, Spain|Santander, Cantabria, Spain|La Coruña, Spain|Zaragoza, Spain|Kharkov, Ukraine|Uzhgorod, Ukraine|Zaporozhye, Ukraine|Chelmsford, United Kingdom|Dundee, United Kingdom|Leicester, United Kingdom|Plymouth, United Kingdom|Caracas, Venezuela",,https://ClinicalTrials.gov/show/NCT00556322,2.0,alimta or taxotere,erlotinib [tarceva],1,1,False,False,alimta or taxotere,erlotinib [tarceva],False,False,1.0,1.0,TRUE,
23,192,758,759,NCT00783471,Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC),DOPERLO,Terminated,No Results Available,Advanced Non-Small Cell Lung Cancer,"Drug: Erlotinib, Docetaxel|Drug: Docetaxel, Erlotinib","Progression free survival (PFS)|To compare the Overall Survival (OS),the Objective Response Rate (ORR) and duration of response|Identify predictive signaling molecules of the EGFR pathway",Hellenic Cooperative Oncology Group,All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,51,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HE 2D/07,8-Nov,10-May,10-Jun,31-Oct-08,,16-Jun-10,"Sotiria Hospital, Athens, Greece|""Alexandra"" Hospital, Athens, Greece|""Attikon"" University Hospital, 2nd Dept. of Internal Medicine, Propaedeutic, Oncology Section, Athens, Greece|Agii Anargiri Cancer Hospital, 3rd Dept. of Medical Oncology, Athens, Greece|Hygeia Hospital, Athens, Greece|University General Hospital of Ioannina, Medical Oncology Dept, Ioannina, Greece|Larissa University Hospital, Larissa, Greece|Metropolitan Hospital, Second Dept of Medical Oncology, Piraeus, Greece|Metropolitan Hospital, 1st Dept. of Medical Oncology, Pireaus, Greece|Patras University Hospital, Dept. of Internal Medicine, Oncology Section, Rio, Patras, Greece|Theagenio Cancer Hospital, 2nd Dept of Medical Oncology, Thessaloniki, Greece|Theagenio Cancer Hospital, 3rd Dept. of Medical Oncology, Thessaloniki, Greece|""Papageorgiou"" Hospital, Thessaloniki, Greece",,https://ClinicalTrials.gov/show/NCT00783471,2.0,"erlotinib, docetaxel","docetaxel, erlotinib",1,1,False,False,"erlotinib, docetaxel","docetaxel, erlotinib",False,False,1.0,1.0,TRUE,
26,200,792,793,NCT00330044,"Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer",,Completed,No Results Available,Inoperable Non Small Cell Lung Cancer,Drug: Premetrexed (Alimta)|Drug: Carboplatin,Response and Progression Free Survival,Sidney Kimmel Cancer Center at Thomas Jefferson University|Eli Lilly and Company|Thomas Jefferson University,All,"18 Years and older   (Adult, Older Adult)",Phase 1,18,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,05C.276|2005-19,6-Apr,9-Aug,9-Oct,25-May-06,,2-Dec-16,"Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00330044,2.0,premetrexed (alimta),carboplatin,1,1,False,False,premetrexed (alimta),carboplatin,False,False,1.0,1.0,TRUE,
29,226,903,904,NCT00231465,Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer,,Completed,Has Results,Non-Small Cell Lung Cancer,Drug: docetaxel (Taxotere®)|Drug: ZD1839,Overall Response Rate (ORR)|Progression Free Survival (PFS) Rate|Overall Survival (OS) Rate,H. Lee Moffitt Cancer Center and Research Institute|AstraZeneca,All,70 Years and older   (Older Adult),Phase 2,44,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MCC-12905|1839US/0205,3-Jul,12-Aug,12-Aug,4-Oct-05,30-Nov-12,3-Mar-17,"H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT00231465,2.0,docetaxel (taxotere®),zd1839,1,1,False,False,docetaxel (taxotere®),iressa,False,False,1.0,1.0,TRUE,
30,231,920,921,NCT00881296,Gemcitabine and Carboplatin for Elderly Patient With Lung Cancer,GEEP,Completed,No Results Available,Non-Small Cell Lung Cancer,Drug: gemcitabine and carboplatin|Drug: Gemcitabine,Efficacy (response rate)|The toxicity profile (adverse event profile),Hamamatsu University,All,76 Years and older   (Older Adult),Phase 2,60,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Hamamatsu 20-34,8-Mar,11-Mar,11-Jun,15-Apr-09,,7-Sep-11,"Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan",,https://ClinicalTrials.gov/show/NCT00881296,2.0,gemcitabine and carboplatin,gemcitabine,1,1,False,False,gemcitabine and carboplatin,gemcitabine,False,False,1.0,1.0,TRUE,
32,256,1079,1080,NCT00004096,Carboplatin Plus Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer,,Completed,No Results Available,Lung Cancer,Drug: carboplatin|Drug: vinorelbine ditartrate,,Northwestern University|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,,Other|NIH,Interventional,Primary Purpose: Treatment,NU 99L2|NU-99L2|NCI-G99-1589,Aug-99,2-Mar,2-Mar,5-Aug-04,,6-Jun-12,"Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT00004096,2.0,carboplatin,vinorelbine ditartrate,1,1,False,False,carboplatin,vinorelbine ditartrate,False,False,1.0,1.0,TRUE,
33,262,1103,1104,NCT00004159,Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor,,Terminated,No Results Available,Lung Cancer,Drug: gemcitabine hydrochloride|Drug: paclitaxel,,University of Alabama at Birmingham|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,54,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000067399|UAB-9720|UAB-F970730006|NCI-G99-1624,Feb-00,Feb-00,Feb-00,26-Jul-04,,20-Nov-13,"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States",,https://ClinicalTrials.gov/show/NCT00004159,2.0,gemcitabine hydrochloride,paclitaxel,1,1,False,False,gemcitabine hydrochloride,paclitaxel,False,False,1.0,1.0,TRUE,
34,264,1124,1125,NCT00003447,Vinorelbine and/or Gemcitabine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer,,Unknown status,No Results Available,Lung Cancer,Drug: gemcitabine hydrochloride|Drug: vinorelbine tartrate,,Istituto Nazionale per lo Studio e la Cura dei Tumori|National Cancer Institute (NCI),All,70 Years and older   (Older Adult),Phase 3,630,Other,Interventional,Allocation: Randomized|Primary Purpose: Treatment,CDR0000066476|ITA-MILES|ITA-GOCSI-MILES|EU-98019,Jul-98,,,21-May-04,,19-Dec-13,"Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy",,https://ClinicalTrials.gov/show/NCT00003447,2.0,gemcitabine hydrochloride,vinorelbine tartrate,1,1,False,False,gemcitabine hydrochloride,vinorelbine tartrate,False,False,1.0,1.0,TRUE,
35,272,1167,1168,NCT00022646,Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,,Completed,No Results Available,Lung Cancer,Drug: gemcitabine hydrochloride|Drug: pemetrexed disodium,tumor response rate|duration of response|time to treatment failure|survival|time to disease progression,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,157,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCCTG-N0026|NCI-2012-02399|CDR0000068838,1-Aug,3-Nov,8-Oct,27-Jan-03,,7-Dec-16,"CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|Siouxland Hematology-Oncology, Sioux City, Iowa, United States|CCOP - Wichita, Wichita, Kansas, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|CCOP - Duluth, Duluth, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CentraCare Health Plaza, Saint Cloud, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Medcenter One Health System, Bismarck, North Dakota, United States|CCOP - Merit Care Hospital, Fargo, North Dakota, United States|Altru Health Systems, Grand Forks, North Dakota, United States|CCOP - Toledo Community Hospital, Toledo, Ohio, United States|CCOP - Geisinger Clinic and Medical Center, Danville, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|CCOP - Sioux Community Cancer Consortium, Sioux Falls, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT00022646,2.0,gemcitabine hydrochloride,pemetrexed disodium,1,1,False,False,gemcitabine hydrochloride,pemetrexed disodium,False,False,1.0,1.0,TRUE,
36,275,1189,1190,NCT00095225,A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer),,Completed,No Results Available,"Non-Small-Cell Lung Carcinoma|Neoplasm Recurrence, Local",Drug: Avastin (bevacizumab)|Drug: Tarceva (erlotinib HCl),To evaluate the safety and preliminary efficacy of combining bevacizumab with chemotherapy or Tarceva relative to chemotherapy alone on patients with previously treated advanced non-small cell lung cancer.,"Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",Phase 2,122,Industry,Interventional,Primary Purpose: Treatment,OSI2950g,4-Jul,,6-Nov,2-Nov-04,,29-Jan-08,"Comprehensive Blood and Cancer Center (TORI), Bakersfield, California, United States|Bay Area Cancer Research Group, Concord, California, United States|Virginia K. Crosson Cancer Center (TORI), Fullerton, California, United States|California Cancer Center, Inc, Greenbrae, California, United States|Wilshire Oncology Medical Group (TORI), Laverne, California, United States|Pacific Shores Medical Group (TORI), Long Beach, California, United States|UCLA Medical Center PVUB 3360, Los Angeles, California, United States|Central Hematology Oncology Medical Group (TORI), Monterey Park, California, United States|North Valley Hematology/Oncology Medical Group (TORI), Northridge, California, United States|Ventura County Hematology-Oncology Specialists (TORI), Oxnard, California, United States|Cancer Care Associates Medical Group (TORI), Redondo Beach, California, United States|UC Davis Cancer Center, Sacramento, California, United States|Kaiser Permanente/ San Diego, San Diego, California, United States|Sansum Santa Barbara Medical Foundation Clinic (TORI), Santa Barbara, California, United States|Santa Barbara Hematology Oncology Medical Group, Inc (TORI), Santa Barbara, California, United States|Kaiser Permanente Northern CA, Vallejo, California, United States|San Diego Cancer Center Medical Group (TORI), Vista, California, United States|Comprehensive Cancer Care Specialist at Boca Raton, Boca Raton, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|The Florida Cancer Institute(TORI), Orlando, Florida, United States|MD Anderson Cancer Ctr- Orlando, Orlando, Florida, United States|Hematology and Oncology of Northeast Georgia, PC (TORI), Athens, Georgia, United States|Medical Oncology Associates, PC (TORI), Augusta, Georgia, United States|Suburban Hematology-Oncology Associates (TORI), Lawrenceville, Georgia, United States|WellStar Cancer Research Office, Marietta, Georgia, United States|Atlanta Cancer Care (TORI), Roswell, Georgia, United States|Rush-Presbyteriam, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola Univ. Medical Center, Maywood, Illinois, United States|Hematology Oncology Consultants, Naperville, Illinois, United States|Oncoloy Hematology Associates of Central Illinois, PC (TORI), Peoria, Illinois, United States|Norton Healthcare Louisville Oncology, Louisville, Kentucky, United States|Ochsner Cancer Inst., New Orleans, Louisiana, United States|Maine Center for Cancer Medicine and Blood Disorders, Scarborough, Maine, United States|Methodist Cancer Center-Oncology Research, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada (TORI), Las Vegas, Nevada, United States|Summit Medical Group Overlook Oncology Center, Summit, New Jersey, United States|Cancer Research of Long Island, Great Neck, New York, United States|Northwestern Carolina Oncology and Hematology, Hickory, North Carolina, United States|Mid Dakota Clinic, Bismarck, North Dakota, United States|Earle A. Chiles Research Institute, Portland, Oregon, United States|Kaiser Permanente Northwest Region, Portland, Oregon, United States|Univ. of Pittsburgh Cancer Center Inst., Pittsburgh, Pennsylvania, United States|University of Tenn. Cancer Ins, Memphis, Tennessee, United States|The West Cancer Clinic, Memphis, Tennessee, United States|M.D. Anderson, Houston, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Internal Medicine Associates of Yakima, Yakima, Washington, United States",,https://ClinicalTrials.gov/show/NCT00095225,2.0,avastin (bevacizumab),tarceva (erlotinib hcl),1,1,False,False,avastin (bevacizumab),tarceva (erlotinib hcl),False,False,1.0,1.0,TRUE,
37,283,1222,1223,NCT00003762,Docetaxel and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer,,Completed,No Results Available,Lung Cancer,Drug: docetaxel|Drug: gemcitabine hydrochloride,response rate|quality of life,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,106,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCCTG-982452|NCI-2012-02294|CDR0000066887,Feb-99,3-Feb,8-May,24-Jun-04,,13-Jul-16,"CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|Siouxland Hematology-Oncology, Sioux City, Iowa, United States|CCOP - Wichita, Wichita, Kansas, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|CCOP - Duluth, Duluth, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CentraCare Clinic, Saint Cloud, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Quain & Ramstad Clinic, P.C., Bismarck, North Dakota, United States|CCOP - Merit Care Hospital, Fargo, North Dakota, United States|Altru Health Systems, Grand Forks, North Dakota, United States|CCOP - Geisinger Clinical and Medical Center, Danville, Pennsylvania, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States",,https://ClinicalTrials.gov/show/NCT00003762,2.0,docetaxel,gemcitabine hydrochloride,1,1,False,False,docetaxel,gemcitabine hydrochloride,False,False,1.0,1.0,TRUE,
38,287,1240,1241,NCT00407550,Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,,Completed,Has Results,Lung Cancer,Drug: gemcitabine HCL|Drug: pemetrexed disodium,Number of Patients With Confirmed Responses|Progression-free Survival|Overall Survival|Adverse Event,Mayo Clinic|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 2,19,Other|NIH,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000516012|P30CA015083|RC0524|06-002282|H3E-US-S061,6-Nov,8-Jan,12-May-10,5-Dec-06,13-Jun-12,2-May-19,"Mayo Clinic Cancer Center, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT00407550,2.0,gemcitabine hcl,pemetrexed disodium,1,1,False,False,gemcitabine hcl,pemetrexed disodium,False,False,1.0,1.0,TRUE,
41,319,1378,1379,NCT00268489,Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,,Completed,No Results Available,Lung Cancer,Biological: bevacizumab|Drug: pemetrexed disodium,Proportion of progression-free patients at 3 months|Response (complete and partial) as assessed by RECIST criteria|Overall survival|Progression-free survival|Duration of response|Time to treatment failure,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,48,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCCTG-N0426|NCI-2012-02681|SWOG-N0426|CDR0000456427,6-May,7-May,10-Apr,22-Dec-05,,6-Jul-16,"Providence Cancer Center, Anchorage, Alaska, United States|Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Eden Medical Center, Castro Valley, California, United States|Saint Rose Hospital, Hayward, California, United States|Highland General Hospital at St. George's University School of Medicine, Oakland, California, United States|Alta Bates Summit Medical Center - Summit Campus, Oakland, California, United States|CCOP - Bay Area Tumor Institute, Oakland, California, United States|Valley Care Medical Center, Pleasanton, California, United States|Doctors Medical Center - San Pablo Campus, San Pablo, California, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Piedmont Hospital, Atlanta, Georgia, United States|Northside Hospital Cancer Center, Atlanta, Georgia, United States|Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|WellStar Cobb Hospital, Austell, Georgia, United States|Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|Kennestone Cancer Center at Wellstar Kennestone Hospital, Marietta, Georgia, United States|Southern Regional Medical Center, Riverdale, Georgia, United States|Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia, United States|Pearlman Comprehensive Cancer Center at South Georgia Medical Center, Valdosta, Georgia, United States|Saint Anthony's Hospital at Saint Anthony's Health Center, Alton, Illinois, United States|Rush-Copley Cancer Care Center, Aurora, Illinois, United States|St. Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital, Canton, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Eureka Community Hospital, Eureka, Illinois, United States|Galesburg Clinic, Galesburg, Illinois, United States|Galesburg Cottage Hospital, Galesburg, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Hopedale Medical Complex, Hopedale, Illinois, United States|Joliet Oncology-Hematology Associates, Limited - West, Joliet, Illinois, United States|McDonough District Hospital, Macomb, Illinois, United States|Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood, Illinois, United States|Good Samaritan Regional Health Center, Mt. Vernon, Illinois, United States|BroMenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center, Normal, Illinois, United States|Community Hospital of Ottawa, Ottawa, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Ottawa, Ottawa, Illinois, United States|Cancer Treatment Center at Pekin Hospital, Pekin, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States|Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF St. Francis Medical Center, Peoria, Illinois, United States|Illinois Valley Community Hospital, Peru, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|St. Margaret's Hospital, Spring Valley, Illinois, United States|Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|St. Francis Hospital and Health Centers - Beech Grove Campus, Beech Grove, Indiana, United States|Saint Anthony Memorial Health Centers, Michigan City, Indiana, United States|Reid Hospital & Health Care Services, Incorporated, Richmond, Indiana, United States|McFarland Clinic, PC, Ames, Iowa, United States|Cedar Rapids Oncology Associates, Cedar Rapids, Iowa, United States|Genesis Regional Cancer Center at Genesis Medical Center, Davenport, Iowa, United States|Mercy Capitol Hospital, Des Moines, Iowa, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at John Stoddard Cancer Center, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates at Mercy Cancer Center, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|John Stoddard Cancer Center at Iowa Lutheran Hospital, Des Moines, Iowa, United States|Mercy Cancer Center at Mercy Medical Center - North Iowa, Mason City, Iowa, United States|McCreery Cancer Center at Ottumwa Regional, Ottumwa, Iowa, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Mercy Medical Center - Sioux City, Sioux City, Iowa, United States|St. Luke's Regional Medical Center, Sioux City, Iowa, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Southwest Medical Center, Liberal, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Tammy Walker Cancer Center at Salina Regional Health Center, Salina, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Cancer Research Center at Boston Medical Center, Boston, Massachusetts, United States|Saint Joseph Mercy Cancer Center, Ann Arbor, Michigan, United States|CCOP - Michigan Cancer Research Consortium, Ann Arbor, Michigan, United States|Oakwood Cancer Center at Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Green Bay Oncology, Limited - Escanaba, Escanaba, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Van Elslander Cancer Center at St. John Hospital and Medical Center, Grosse Pointe Woods, Michigan, United States|Green Bay Oncology, Limited - Iron Mountain, Iron Mountain, Michigan, United States|Foote Hospital, Jackson, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|Ted B. Wahby Cancer Center at Mount Clemens General Hospital, Mount Clemens, Michigan, United States|Seton Cancer Institute - Saginaw, Saginaw, Michigan, United States|St. John Macomb Hospital, Warren, Michigan, United States|Alexandria, Minnesota, United States|MeritCare Clinic - Bemidji, Bemidji, Minnesota, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|CCOP - Duluth, Duluth, Minnesota, United States|Miller-Dwan Medical Center, Duluth, Minnesota, United States|St. Mary's - Duluth Clinic Cancer Center, Duluth, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Fergus Falls, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Meeker County Memorial Hospital, Lichfield, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Minnesota Oncology Hematology, PA at Maplewood Cancer Center, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|Chippewa County - Montevideo Hospital, Montevideo, Minnesota, United States|Hubert H. Humphrey Cancer Center at North Memorial Medical Center, Robbinsdale, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Coborn Cancer Center, Saint Cloud, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Saint Francis Cancer Center, Shakopee, Minnesota, United States|St. Joseph's Hospital, St Paul, Minnesota, United States|CentraCare Clinic - River Campus, St. Cloud, Minnesota, United States|Park Nicollet Health Services, St. Louis Park, Minnesota, United States|Regions Hospital Cancer Care Center, St. Paul, Minnesota, United States|United Hospital, St. Paul, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States|Woodwinds Health Campus, Woodbury, Minnesota, United States|Regional Cancer Center at Singing River Hospital, Pascagoula, Mississippi, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Missouri Regional Cancer Center at Southeast Missouri Hospital, Gape Girardeau, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Arch Medical Services, Incorporated at Center for Cancer Care Research, Saint Louis, Missouri, United States|David C. Pratt Cancer Center at St. John's Mercy, Saint Louis, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|St. John's Regional Health Center, Springfield, Missouri, United States|Hulston Cancer Center at Cox Medical Center South, Springfield, Missouri, United States|Missouri Baptist Cancer Center, St. Louis, Missouri, United States|CCOP - St. Louis-Cape Girardeau, St. Louis, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies - Billings, Billings, Montana, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|St. Vincent Healthcare, Billings, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Deaconess Billings Clinic - Downtown, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|St. James Community Hospital, Butte, Montana, United States|Big Sky Oncology, Great Falls, Montana, United States|Sletten Regional Cancer Institute at Benefis Healthcare, Great Falls, Montana, United States|St. Peter's Hospital, Helena, Montana, United States|Glacier Oncology, PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Community Medical Center, Missoula, Montana, United States|Guardian Oncology and Center for Wellness, Missoula, Montana, United States|Montana Cancer Specialists at Montana Cancer Center, Missoula, Montana, United States|Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States|Good Samaritan Cancer Center at Good Samaritan Hospital, Kearney, Nebraska, United States|Cancer Resource Center - Lincoln, Lincoln, Nebraska, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Adirondack Cancer Care - Glens Falls, Glens Falls, New York, United States|Randolph Hospital, Asheboro, North Carolina, United States|Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States|Moses Cone Regional Cancer Center at Wesley Long Community Hospital, Greensboro, North Carolina, United States|Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Annie Penn Cancer Center, Reidsville, North Carolina, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Iredell Memorial Hospital, Statesville, North Carolina, United States|Bismarck Cancer Center, Bismarck, North Dakota, United States|Cancer Care Center at Medcenter One Hospital, Bismarck, North Dakota, United States|Mid Dakota Clinic, PC, Bismarck, North Dakota, United States|St. Alexius Medical Center, Bismarck, North Dakota, United States|CCOP - MeritCare Hospital, Fargo, North Dakota, United States|MeritCare Medical Group, Fargo, North Dakota, United States|Altru Cancer Center at Altru Hospital, Grand Forks, North Dakota, United States|Adena Regional Medical Center, Chillicothe, Ohio, United States|Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Grant Riverside Cancer Services, Columbus, Ohio, United States|Mount Carmel Health - West Hospital, Columbus, Ohio, United States|Doctors Hospital at Ohio Health, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital, Dayton, Ohio, United States|David L. Rike Cancer Center at Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Cancer Care Center, Dayton, Ohio, United States|Veterans Affairs Medical Center - Dayton, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|Grady Memorial Hospital, Delaware, Ohio, United States|Blanchard Valley Medical Associates, Findlay, Ohio, United States|Charles F. Kettering Memorial Hospital, Kettering, Ohio, United States|Fairfield Medical Center, Lancaster, Ohio, United States|Strecker Cancer Center at Marietta Memorial Hospital, Marietta, Ohio, United States|Middletown Regional Hospital, Middletown, Ohio, United States|Licking Memorial Cancer Care Program at Licking Memorial Hospital, Newark, Ohio, United States|Mercy Medical Center, Springfield, Ohio, United States|Community Hospital of Springfield and Clark County, Springfield, Ohio, United States|UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States|Mount Carmel Cancer Services at Mount Carmel St. Ann's Hospital, Westerville, Ohio, United States|United States Air Force Medical Center - Wright-Patterson, Wright-Patterson Afb, Ohio, United States|Ruth G. McMillan Cancer Center at Greene Memorial Hospital, Xenia, Ohio, United States|Genesis - Good Samaritan Hospital, Zanesville, Ohio, United States|Natalie Warren Bryant Cancer Center at St. Francis Hospital, Tulsa, Oklahoma, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Legacy Good Samaritan Hospital & Medical Center Comprehensive Cancer Center, Portland, Oregon, United States|Providence Cancer Center at Providence Portland Medical Center, Portland, Oregon, United States|CCOP - Columbia River Oncology Program, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Legacy Emanuel Hospital and Health Center & Children's Hospital, Portland, Oregon, United States|Salem Hospital Regional Cancer Care Services, Salem, Oregon, United States|Legacy Meridian Park Hospital, Tualatin, Oregon, United States|Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest, Allentown, Pennsylvania, United States|Guthrie Cancer Center at Guthrie Clinic Sayre, Sayre, Pennsylvania, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Medical X-Ray Center, PC, Sioux Falls, South Dakota, United States|Sioux Valley Hospital and University of South Dakota Medical Center, Sioux Falls, South Dakota, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|Danville Regional Medical Center, Danville, Virginia, United States|St. Joseph Cancer Center, Bellingham, Washington, United States|Olympic Hematology and Oncology, Bremerton, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Harborview Medical Center, Seattle, Washington, United States|Minor and James Medical, PLLC, Seattle, Washington, United States|Group Health Central Hospital, Seattle, Washington, United States|Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle, Washington, United States|Polyclinic First Hill, Seattle, Washington, United States|University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States|Cancer Care Northwest - Spokane South, Spokane, Washington, United States|Southwest Washington Medical Center Cancer Center, Vancouver, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Green Bay Oncology, Limited at St. Vincent Hospital, Green Bay, Wisconsin, United States|Green Bay Oncology, Limited at St. Mary's Hospital, Green Bay, Wisconsin, United States|St. Mary's Hospital Medical Center - Green Bay, Green Bay, Wisconsin, United States|St. Vincent Hospital Regional Cancer Center, Green Bay, Wisconsin, United States|Franciscan Skemp Healthcare, La Crosse, Wisconsin, United States|Bay Area Cancer Care Center at Bay Area Medical Center, Marinette, Wisconsin, United States|Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, Wisconsin, United States|Green Bay Oncology, Limited - Sturgeon Bay, Sturgeon Bay, Wisconsin, United States|Welch Cancer Center at Sheridan Memorial Hospital, Sheridan, Wyoming, United States",,https://ClinicalTrials.gov/show/NCT00268489,2.0,bevacizumab,pemetrexed disodium,1,1,False,False,bevacizumab,pemetrexed disodium,False,False,1.0,1.0,TRUE,
45,338,1464,1465,NCT02364609,Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib,,"Active, not recruiting",No Results Available,Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,Drug: Afatinib Dimaleate|Biological: Pembrolizumab,Maximum tolerated dose (MTD) recommended dose of pembrolizumab in combination with lead in pembrolizumab and afatinib dimaleate|Recommended phase II dose|Overall response rate per RECIST 1.1|Progression free survival,"University of California, Davis|National Cancer Institute (NCI)",All,"18 Years and older   (Adult, Older Adult)",Phase 1,38,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,704874|UCDCC#250|1200.237|P30CA093373|51657|NCI-2015-00126,15-Sep,21-Oct-19,21-Oct-19,18-Feb-15,,2-May-19,"University of California Davis Comprehensive Cancer Center, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT02364609,2.0,afatinib dimaleate,pembrolizumab,1,1,False,False,afatinib dimaleate,pembrolizumab,False,False,1.0,1.0,TRUE,
46,342,1487,1488,NCT00065182,Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer,,Completed,Has Results,"Lung Cancer, Non-Small Cell|Non-Small-Cell Lung Cancer",Drug: Topotecan/Docetaxel combination|Drug: Docetaxel,"Median Time of Overall Survival|Number of Participants With One-year Survival|Median Time to Progression|Response Rate|Response Duration|Time to Response-assessed Every 8 Weeks|Assessment of Quality of Life-assessed Every 4 Weeks|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Grade 1, 2, 3 or 4 Hematologic Toxicities|Number of Participants With Grade 3 or 4 Clinical Chemical Toxicities|Number of Participants With Clinically Significant Abnormal Vital Signs Data",GlaxoSmithKline,All,"18 Years and older   (Adult, Older Adult)",Phase 2,399,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,104864/615|2004-002892-17,14-Aug-03,30-Aug-07,30-Aug-07,18-Jul-03,24-Jun-19,24-Jun-19,"GSK Investigational Site, Huntsville, Alabama, United States|GSK Investigational Site, Mobile, Alabama, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Poway, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Boca Raton, Florida, United States|GSK Investigational Site, Boca Raton, Florida, United States|GSK Investigational Site, Lakeland, Florida, United States|GSK Investigational Site, Miami Shores, Florida, United States|GSK Investigational Site, Orange Park, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Stuart, Florida, United States|GSK Investigational Site, Columbus, Georgia, United States|GSK Investigational Site, Decatur, Illinois, United States|GSK Investigational Site, Elk Grove Village, Illinois, United States|GSK Investigational Site, Skokie, Illinois, United States|GSK Investigational Site, Urbana, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Bowling Green, Kentucky, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Baton Rouge, Louisiana, United States|GSK Investigational Site, Lafayette, Louisiana, United States|GSK Investigational Site, Lake Charles, Louisiana, United States|GSK Investigational Site, Frederick, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Grosse Pointe Woods, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Robbinsdale, Minnesota, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Springfield, Missouri, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Reno, Nevada, United States|GSK Investigational Site, Hackensack, New Jersey, United States|GSK Investigational Site, Bronx, New York, United States|GSK Investigational Site, Buffalo, New York, United States|GSK Investigational Site, East Syracuse, New York, United States|GSK Investigational Site, Manhasset, New York, United States|GSK Investigational Site, New Hyde Park, New York, United States|GSK Investigational Site, Nyack, New York, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Fayetteville, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Dunmore, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Columbia, South Carolina, United States|GSK Investigational Site, Hilton Head Island, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Irving, Texas, United States|GSK Investigational Site, Tyler, Texas, United States|GSK Investigational Site, Abingdon, Virginia, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Sheboygan, Wisconsin, United States|GSK Investigational Site, Casper, Wyoming, United States|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Moncton, New Brunswick, Canada|GSK Investigational Site, Kingston, Ontario, Canada|GSK Investigational Site, Kitchener, Ontario, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, St. Catharines, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Weston, Ontario, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Levis, Quebec, Canada|GSK Investigational Site, Sainte-Foy, Quebec, Canada|GSK Investigational Site, Kielce, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Szczecin Zdunowo 20, Poland",,https://ClinicalTrials.gov/show/NCT00065182,2.0,topotecan/docetaxel combination,docetaxel,1,1,False,False,topotecan/docetaxel combination,docetaxel,False,False,1.0,1.0,TRUE,
47,344,1499,1500,NCT00075517,Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer,,Unknown status,No Results Available,Lung Cancer,Drug: docetaxel|Drug: gemcitabine hydrochloride,Response rate|Progression-free survival|Overall survival|Tolerability|Quality of life,GERCOR - Multidisciplinary Oncology Cooperative Group|National Cancer Institute (NCI),All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 2,,Other,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000346806|FRE-GERCOR-DOCEGEM-B00-2|EU-20331,3-Sep,,,12-Jan-04,,24-Jul-08,"Hopital Avicenne, Bobigny, France|Centre Jean Bernard, Le Mans, France|Hopital Perpetuel Secours, Levallois-Perret, France|Centre de Radiotherapie et Oncologie Saint-Faron, Mareuil Les Meaux, France|Clinique de Docteur Terrioux, Meaux, France|American Hospital of Paris, Neuilly Sur Seine, France|Hopital Tenon, Paris, France|Clinique les Bleuets, Reims, France|Polyclinique De Courlancy, Reims, France|Centre Rene Huguenin, Saint Cloud, France|Clinique Francois, Saint-Dizier, France|Hopital Paul Brousse, Villejuif, France",,https://ClinicalTrials.gov/show/NCT00075517,2.0,docetaxel,gemcitabine hydrochloride,1,1,False,False,docetaxel,gemcitabine hydrochloride,False,False,1.0,1.0,TRUE,
49,353,1535,1536,NCT00085839,Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2,,Completed,Has Results,Non-Small Cell Lung Cancer,"Drug: Tarceva (Trademark) (erlotinib HCl, OSI-774)|Drug: Combination carboplatin and paclitaxel",Progression-free Survival|Overall Survival|Best Tumor Response,OSI Pharmaceuticals|Astellas Pharma Inc,All,"18 Years and older   (Adult, Older Adult)",Phase 2,103,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,OSI-774-201,4-Feb,7-Mar,7-Mar,17-Jun-04,22-Apr-11,9-Aug-12,"California Cancer Care, Inc., Greenbrae, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Mount Sinai Cancer Center, Miami Beach, Florida, United States|University of Miami, Miami, Florida, United States|Evanston Northwestern Healthcare, Evanston, Illinois, United States|Oncology/Hematology Associates of Central Illinois, Peoria, Illinois, United States|Norton Healthcare, Inc., Louisville, Kentucky, United States|Maryland Hematology/Oncology Associates, Baltimore, Maryland, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|Weill Medical College of Cornell University, New York, New York, United States|FEK Addo, PC, Bismarck, North Dakota, United States|Gabrail Cancer Center, Canton, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Charleston Hematology Oncology, Charleston, South Carolina, United States|East Tennessee Oncology/Hematology, PC, Knoxville, Tennessee, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00085839,2.0,"tarceva (trademark) (erlotinib hcl, osi-774)",combination carboplatin and paclitaxel,1,1,False,False,tarceva,combination carboplatin and paclitaxel,False,False,1.0,1.0,TRUE,
50,354,1536,1537,NCT00309998,Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,,Completed,No Results Available,Lung Cancer,Biological: bevacizumab|Drug: vinorelbine tartrate,"Median time to disease progression by imaging study every 6 weeks|Response rate by imaging study every 6 weeks|Median survival|Safety as measured by toxicity (e.g thromboembolism, bleeding, or bowel perforation) every three weeks or as required",University of Rochester,All,70 Years and older   (Older Adult),Phase 2,50,Other,Interventional,Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000465498|URCC-U1505|GENENTECH-AVF3328S,5-Sep,7-May,,3-Apr-06,,17-Sep-14,"James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States",,https://ClinicalTrials.gov/show/NCT00309998,2.0,bevacizumab,vinorelbine tartrate,1,1,False,False,bevacizumab,vinorelbine tartrate,False,False,1.0,1.0,TRUE,
51,358,1561,1562,NCT00278460,Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer,,Completed,No Results Available,Lung Cancer,Drug: docetaxel|Drug: gemcitabine hydrochloride,patient response rate to weekly taxotere and gemcitabine|Evaluate toxicity of weekly Taxotere and Gemcitabine,Wake Forest University Health Sciences|National Cancer Institute (NCI),All,"18 Years to 120 Years   (Adult, Older Adult)",Phase 2,49,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000462116|CCCWFU-62199|AVENTIS-CCCWFU-62199|AG-CCCWFU-62199|CCCWFU-BG99-322,Nov-00,6-Feb,7-Sep,18-Jan-06,,19-Jan-17,,,https://ClinicalTrials.gov/show/NCT00278460,2.0,docetaxel,gemcitabine hydrochloride,1,1,False,False,docetaxel,gemcitabine hydrochloride,False,False,1.0,1.0,TRUE,
52,359,1569,1570,NCT01063283,Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC,AVF4759,Completed,No Results Available,Advanced Non-squamous Non-Small Cell Lung Cancer,Drug: Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg|Drug: Carboplatin and Pemetrexed with Bevacizumab 15 mg/kg,Does a higher dose of bevacizumab have any effect on changes in blood pressure|Response rate|Change in tumor size|Progression free survival,"University of Chicago|Genentech, Inc.",All,"18 Years to 89 Years   (Adult, Older Adult)",Not Applicable,70,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,10-014-B,10-Mar,16-Jun,16-Jun,5-Feb-10,,1-Jun-17,"The University of Chicago Medical Center, Chicago, Illinois, United States|North Shore University Health System, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States",,https://ClinicalTrials.gov/show/NCT01063283,2.0,carboplatin and pemetrexed with bevacizumab 7.5 mg/kg,carboplatin and pemetrexed with bevacizumab 15 mg/kg,1,1,False,False,carboplatin and pemetrexed with bevacizumab,carboplatin and pemetrexed with bevacizumab,False,False,1.0,1.0,TRUE,
53,361,1577,1578,NCT01404260,Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer,ISCAN,Completed,Has Results,Non-small Cell Lung Cancer,Drug: Gefitinib|Drug: Gemcitabine +Carboplatin,Progression Free Survival,"Guangdong Association of Clinical Trials|First Hospital of Jilin University|Ruijin Hospital|Fudan University|Jiangsu Cancer Institute & Hospital|Nanjing PLA General Hospital|Wuxi No. 4 People's Hospital|The First Affiliated Hospital of Soochow University|Second Affiliated Hospital, School of Medicine, Zhejiang University|Sir Run Run Shaw Hospital|Henan Cancer Hospital|Changhai Hospital|NanJing PLA 81 Hospital|First People's Hospital of Hangzhou",All,"18 Years to 75 Years   (Adult, Older Adult)",Phase 3,219,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CTONG 1102,11-Jun,15-Mar,15-Oct,28-Jul-11,27-Jan-17,27-Jan-17,"Shanghai Lung Tumor Clinical Center,Shanghai Chest Hospital, Shanghai, Shanghai, China",,https://ClinicalTrials.gov/show/NCT01404260,2.0,gefitinib,gemcitabine +carboplatin,1,1,False,False,gefitinib,gemcitabine +carboplatin,False,False,1.0,1.0,TRUE,
54,369,1606,1607,NCT00387322,Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors,,Completed,No Results Available,"Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Drug: erlotinib hydrochloride|Drug: pemetrexed disodium,Safety and feasibility (Phase I)|Response rate (Phase II)|Toxicity (Phase I)|Maximum tolerated dose (Phase I)|Preliminary efficacy (Phase I)|Overall survival (Phase II)|Progression-free survival (Phase II)|Frequency and severity of toxicity (Phase II),"University of California, Davis|National Cancer Institute (NCI)",All,"18 Years and older   (Adult, Older Adult)",Phase 1|Phase 2,42,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000505895|P30CA093373|UCDCC-159|200412741,5-Mar,7-Oct,9-May,13-Oct-06,,29-Mar-10,"University of California Davis Cancer Center, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT00387322,2.0,erlotinib hydrochloride,pemetrexed disodium,1,1,False,False,erlotinib hydrochloride,pemetrexed disodium,False,False,1.0,1.0,TRUE,
57,379,1663,1664,NCT00446225,Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients With Mutations in the TK Domain of EGFR,,Completed,No Results Available,Non-Small Cell Lung Cancer,Drug: Erlotinib (Tarceva)|Drug: Carboplatin // Gemcitabine // Docetaxel //Cisplatin,Progression Free-survival|Objective Response|One year survival|Overall survival|Safety incidence|Life quality|Molecular markers related to EGFR and study pathology,Spanish Lung Cancer Group,All,"18 Years and older   (Adult, Older Adult)",Phase 3,174,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,EURTAC-SLCG // GECP06/01|EudraCT:2006-003568-73,7-Feb,9-Dec,12-Dec,12-Mar-07,,11-Mar-13,"Centre Hospitalier Universitaire D'Angers, Angers, France|Hôpital Auguste Morvan, Brest, France|Centre François Baclesse, Caen, France|Centre Hospitalier René Dubos, Cergy Pontoise, France|Centre Hospitalier Intercommunal, Creteil, France|Hôpital A. Mignot, Le Chesnay, France|Centre Hospitalier Du Mans, Le Mans, France|Centre Oscar Lambret, Lille, France|Hôpital du Cluzeau, Limoges, France|Centre Hospitalier Régional, Longjumeau, France|Centre Hospitalier de Meaux, Meaux, France|Centre Hospitalier de Mulhouse, Mulhouse, France|Hôpital Saint Antoine, Paris, France|Centre Hospitalier, Perigueux, France|Centre Hospitalier de La Région D'Annecy, Pringy, France|CHU Rennes Hôpital Ponchaillou, Rennes, France|Centre Hosiptalier Genéral de Roanne, Roanne, France|Institut de Cancérologie de La Loire, St-Priest en Jarez, France|Hôpital Larrey, Toulouse, France|CRO di Aviano, Aviano, Italy|AO Materdomini, Catanzaro, Italy|AOU Policlinico G. Martino, Messina, Italy|AO Monaldi, Napoli, Italy|Casa di Cura ""La Maddalena"", Palermo, Italy|Istituti Fisioterapici Ospitalieri, Roma, Italy|AO S.Camillo Forlanini, Roma, Italy|Università di Roma ""La Sapienza"" Az.Policlinico Umb.I°, Roma, Italy|PO di SS.ma Annunziata, Sassari, Italy|H. Virgen de los Lirios, Alcoy, Alicante, Spain|H. Torrevieja Salud, Torrevieja, Alicante, Spain|ICO - H. Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital de Mataró, Mataró, Barcelona, Spain|H. Marqués de Valdecilla, Santander, Cantabria, Spain|F.H.Alcorcón, Alcorcon, Madrid, Spain|H. Fuenlabrada, Fuenlabrada, Madrid, Spain|H. Son Dureta, Palma de Mallorca, Mallorca, Spain|H. Ntra. Sra. de la Candelaria, Santa Cruz de Tenerife, Tenerife, Spain|Hospital de Cruces, Baracaldo, Vizcaya, Spain|H.G.U. Alicante, Alicante, Spain|H. Santa Creu i Sant Pau, Barcelona, Spain|Instituto Universitario Dexeus, Barcelona, Spain|H.U.Vall D´Hebrón, Barcelona, Spain|H. Clinic i Provincial, Barcelona, Spain|H. Althaia, Barcelona, Spain|H. Duran i Reynals-ICO, Barcelona, Spain|H. Provincial de Castellón, Castellón, Spain|H. Reina Sofía, Córdoba, Spain|ICO Girona -H. Dr. Josep Trueta, Girona, Spain|Hospital Insular Gran Canaria, Gran Canaria, Spain|H. Virgen de las Nieves, Granada, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Complejo Hosp. Univ. Juan Canalejo, La Coruña, Spain|Hospital San Millan Y San Pedro, Logroño, Spain|H. Arnau de Vilanova, Lérida, Spain|H. de la Princesa, Madrid, Spain|H. Gregorio Marañón, Madrid, Spain|H. Ruber Internacional, Madrid, Spain|H.U. Puerta de Hierro, Madrid, Spain|Fundación Jimenez Diaz, Madrid, Spain|Hospial Clinico San Carlos, Madrid, Spain|H. La Paz, Madrid, Spain|H. 12 de Octubre, Madrid, Spain|H. Ramon y Cajal, Madrid, Spain|H. Carlos Haya, Málaga, Spain|H.C.Universitario Virgen de la Victoria, Málaga, Spain|H. Son Llàtzer, Palma de Mallorca, Spain|Clinica Rotger, Palma de Mallorca, Spain|H. de Donostia, San Sebastian, Spain|H. Virgen del Rocío, Sevilla, Spain|H. Nuestra Sra. de Valme, Sevilla, Spain|H.C.U.Valencia, Valencia, Spain|H. General U. de Valencia, Valencia, Spain|H. Arnau de Vilanova Valencia, Valencia, Spain|H. Dr. Peset, Valencia, Spain|H. Miguel Servet, Zaragoza, Spain|H. Clínico Lozano Blesa, Zaragoza, Spain",,https://ClinicalTrials.gov/show/NCT00446225,2.0,erlotinib (tarceva),carboplatin // gemcitabine // docetaxel //cisplatin,1,1,False,False,erlotinib (tarceva),carboplatin // gemcitabine // docetaxel //cisplatin,False,False,1.0,1.0,TRUE,
58,380,1669,1670,NCT03527108,"Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC",,Not yet recruiting,No Results Available,Non Small Cell Lung Cancer,"Drug: Nivolumab, ramucirumab|Drug: Nivolumab",Number of patients with progression free survival (PFS) at 6 months in IO naive patients.treated with nivolumab and ramucirumab combination therapy vs the nivolumab monotherapy|Disease control rate (DCR) in IO experienced patients.treated with nivolumab and ramucirumab combination therapy|Overall Response Rate (ORR) in IO naive patients treated with nivolumab and ramucirumab combination therapy|Overall Response Rate in IO naive patients treated with nivolumab monotherapy|Number of patients with treatment related toxicities in IO naive patients treated with nivolumab and ramucirumab combination therapy|Number of patients with treatment related toxicities in IO naive patients treated with nivolumab monotherapy|Overall survival in IO naive patients treated with nivolumab and ramucirumab combination.|Overall survival in IO naive patients treated with nivolumab monotherapy|Number of patients with PFS at 6 months in IO experienced patients treated with nivolumab and ramucirumab combination therapy .|ORR in IO experienced patients treated with nivolumab and ramucirumab combination therapy .|Number of patients with treatment related toxicities in IO experienced patients treated with nivolumab and ramucirumab combination therapy .|Overall survival in IO experienced patients treated with nivolumab and ramucirumab combination therapy .,Fox Chase Cancer Center|Bristol-Myers Squibb|Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",Phase 2,117,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,18-1026|TH-125,1-Dec-19,1-Apr-23,1-Apr-24,16-May-18,,18-Jun-19,"Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03527108,2.0,"nivolumab, ramucirumab",nivolumab,1,1,False,False,"nivolumab, ramucirumab",nivolumab,False,False,1.0,1.0,TRUE,
59,388,1713,1714,NCT00738881,Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer,MARVEL,Terminated,Has Results,Recurrent Non-Small Cell Lung Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer,Drug: Erlotinib Hydrochloride|Drug: Pemetrexed Disodium,Progression-free Survival (PFS)|Time to Treatment Failure|Overall Survival|Confirmed Response Rate Defined as Complete Response (CR) or a Partial Response (PR) Per Response Evaluation Criteria In Solid Tumors (RECIST),National Cancer Institute (NCI)|Cancer and Leukemia Group B|Eastern Cooperative Oncology Group|NCIC Clinical Trials Group|Southwest Oncology Group,All,"18 Years and older   (Adult, Older Adult)",Phase 3,23,NIH|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCI-2009-00663|CDR0000612010|NCCTG-N0723|CALGB-30802|CAN-NCIC-BRC4|N0723|U10CA180821|U10CA025224,8-Oct,11-Dec,14-Dec,21-Aug-08,2-Oct-14,29-Oct-15,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Sparks Regional Medical Center, Fort Smith, Arkansas, United States|Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States|Kaiser Permanente-Fremont, Fremont, California, United States|Fremont - Rideout Cancer Center, Marysville, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Valley Care Health System - Pleasanton, Pleasanton, California, United States|Kaiser Permanente-Redwood City, Redwood City, California, United States|Kaiser Permanente-Richmond, Richmond, California, United States|Kaiser Permanente-Roseville, Roseville, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente-South Sacramento, Sacramento, California, United States|Kaiser Permanente - Sacramento, Sacramento, California, United States|Kaiser Permanente-San Francisco, San Francisco, California, United States|Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States|Kaiser Permanente San Leandro, San Leandro, California, United States|Kaiser Permanente-San Rafael, San Rafael, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Kaiser Permanente-Santa Rosa, Santa Rosa, California, United States|Kaiser Permanente-South San Francisco, South San Francisco, California, United States|Kaiser Permanente-Stockton, Stockton, California, United States|Tahoe Forest Cancer Center, Truckee, California, United States|Kaiser Permanente Medical Center-Vacaville, Vacaville, California, United States|Kaiser Permanente-Vallejo, Vallejo, California, United States|Kaiser Permanente-Walnut Creek, Walnut Creek, California, United States|The Medical Center of Aurora, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Exempla Saint Joseph Hospital, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Colorado Cancer Research Program CCOP, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|North Suburban Medical Center, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Bristol Hospital, Bristol, Connecticut, United States|Middlesex Hospital, Middletown, Connecticut, United States|Lynn Regional Cancer Center - West, Boca Raton, Florida, United States|Boca Raton Comprehensive Cancer Center, Boca Raton, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|MacNeal Hospital and Cancer Center, Berwyn, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Graham Hospital Association, Canton, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Hematology and Oncology Associates, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Eureka Hospital, Eureka, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Galesburg Cottage Hospital, Galesburg, Illinois, United States|Illinois CancerCare Galesburg, Galesburg, Illinois, United States|Illinois CancerCare-Cottage, Galesburg, Illinois, United States|Illinois CancerCare-Havana, Havana, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Hematology Oncology Associates of Illinois-Highland Park, Highland Park, Illinois, United States|Hopedale Medical Complex - Hospital, Hopedale, Illinois, United States|Midwest Center for Hematology Oncology, Joliet, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|NorthShore Hematology Oncology-Libertyville, Libertyville, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Mcdonough District Hospital, Macomb, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Holy Family Medical Center, Monmouth, Illinois, United States|Illinois CancerCare-Monmouth, Monmouth, Illinois, United States|DuPage Medical Group-Ogden, Naperville, Illinois, United States|Illinois Cancer Specialists-Niles, Niles, Illinois, United States|Bromenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center Foundation, Normal, Illinois, United States|Illinois CancerCare-Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Ottawa Regional Hospital and Healthcare Center, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Pekin Cancer Treatment Center, Pekin, Illinois, United States|Pekin Hospital, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Illinois Oncology Research Association CCOP, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois Valley Hospital, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Hematology Oncology Associates of Illinois - Skokie, Skokie, Illinois, United States|Illinois CancerCare-Spring Valley, Spring Valley, Illinois, United States|Saint Margaret's Hospital, Spring Valley, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Franciscan St. Francis Health-Beech Grove, Beech Grove, Indiana, United States|Reid Hospital and Health Care Services, Richmond, Indiana, United States|McFarland Clinic PC-William R Bliss Cancer Center, Ames, Iowa, United States|Hematology Oncology Associates-Quad Cities, Bettendorf, Iowa, United States|Cedar Rapids Oncology Association, Cedar Rapids, Iowa, United States|Mercy Hospital, Cedar Rapids, Iowa, United States|Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Genesis Medical Center - East Campus, Davenport, Iowa, United States|Genesis Medical Center - West Campus, Davenport, Iowa, United States|Mercy Capitol, Des Moines, Iowa, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|Iowa Oncology Research Association CCOP, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Iowa Lutheran Hospital, Des Moines, Iowa, United States|Siouxland Regional Cancer Center, Sioux City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|Saint Luke's Regional Medical Center, Sioux City, Iowa, United States|Covenant Medical Center, Waterloo, Iowa, United States|Hospital District Sixth of Harper County, Anthony, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Shawnee Mission Medical Center-KCCC, Shawnee Mission, Kansas, United States|Stormont-Vail Regional Health Center, Topeka, Kansas, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|The Memorial Hospital at Easton, Easton, Maryland, United States|Cancer Trials Support Unit, Rockville, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Steward Saint Elizabeth's Medical Center, Brighton, Massachusetts, United States|Cape Cod Hospital, Hyannis, Massachusetts, United States|Bixby Medical Center, Adrian, Michigan, United States|Hickman Cancer Center, Adrian, Michigan, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Michigan Cancer Research Consortium CCOP, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Spectrum Health Big Rapids Hospital, Big Rapids, Michigan, United States|Oakwood Hospital and Medical Center, Dearborn, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Regional Medical Center-West Flint Campus, Flint, Michigan, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Mercy Memorial Hospital, Monroe, Michigan, United States|Toledo Clinic Cancer Centers-Monroe, Monroe, Michigan, United States|Mercy Health Mercy Campus, Muskegon, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Saint Joseph Mercy Port Huron, Port Huron, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Hutchinson Area Health Care, Hutchinson, Minnesota, United States|Meeker County Memorial Hospital, Litchfield, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Minnesota Cooperative Group Outreach Program, Minneapolis, Minnesota, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Truman Medical Center, Kansas City, Missouri, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Saint Joseph Health Center, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Liberty Hospital, Liberty, Missouri, United States|Liberty Radiation Oncology Center, Liberty, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis University Hospital, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Center for Cancer Care and Research, Saint Louis, Missouri, United States|Montana Cancer Consortium NCORP, Billings, Montana, United States|Northern Rockies Radiation Oncology Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Frontier Cancer Center and Blood Institute-Billings, Billings, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Berdeaux, Donald MD (UIA Investigator), Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Glacier Oncology PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Guardian Oncology and Center for Wellness, Missoula, Montana, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Veterans Adminstration New Jersey Health Care System, East Orange, New Jersey, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|Fox Chase Cancer Center at Virtua Memorial Hospital of Burlington County, Mount Holly, New Jersey, United States|Riverview Medical Center/Booker Cancer Center, Red Bank, New Jersey, United States|Virtua West Jersey Hospital Voorhees, Voorhees, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Syracuse Veterans Administration Medical Center, Syracuse, New York, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|Margaret R Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Rutherford Hospital, Rutherfordton, North Carolina, United States|Southeast Cancer Consortium-Upstate NCORP, Winston-Salem, North Carolina, United States|Mid Dakota Clinic, Bismarck, North Dakota, United States|Saint Alexius Medical Center, Bismarck, North Dakota, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Altru Cancer Center, Grand Forks, North Dakota, United States|Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio, United States|North Coast Cancer Care-Clyde, Clyde, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Dayton CCOP, Dayton, Ohio, United States|Hematology Oncology Center Incorporated, Elyria, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Lima Memorial Hospital, Lima, Ohio, United States|Saint Luke's Hospital, Maumee, Ohio, United States|Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States|Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio, United States|Saint Charles Hospital, Oregon, Ohio, United States|Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio, United States|North Coast Cancer Care, Sandusky, Ohio, United States|Flower Hospital, Sylvania, Ohio, United States|Mercy Hospital of Tiffin, Tiffin, Ohio, United States|The Toledo Hospital/Toledo Children's Hospital, Toledo, Ohio, United States|Saint Vincent Mercy Medical Center, Toledo, Ohio, United States|University of Toledo, Toledo, Ohio, United States|Toledo Community Hospital Oncology Program CCOP, Toledo, Ohio, United States|Mercy Saint Anne Hospital, Toledo, Ohio, United States|Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Fulton County Health Center, Wauseon, Ohio, United States|Clinton Memorial Hospital, Wilmington, Ohio, United States|Greene Memorial Hospital, Xenia, Ohio, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazleton, Hazleton, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Mercy Hospital, Scranton, Pennsylvania, United States|Scranton Hematology Oncology, Scranton, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Mount Nittany Medical Center, State College, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|AnMed Health Hospital, Anderson, South Carolina, United States|Spartanburg Medical Center, Spartanburg, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|Danville Regional Medical Center, Danville, Virginia, United States|Fredericksburg Oncology Inc, Fredericksburg, Virginia, United States|Memorial Hospital Of Martinsville, Martinsville, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada",,https://ClinicalTrials.gov/show/NCT00738881,2.0,erlotinib hydrochloride,pemetrexed disodium,1,1,False,False,erlotinib hydrochloride,pemetrexed disodium,False,False,1.0,1.0,TRUE,
60,390,1717,1718,NCT00026156,S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer,,Completed,No Results Available,Lung Cancer,Drug: docetaxel|Drug: vinorelbine tartrate,,Southwest Oncology Group|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",Phase 2,125,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CDR0000068991|S0027|U10CA032102,1-Nov,4-Jul,8-Nov,27-Jan-03,,15-Feb-13,"MBCCOP - Gulf Coast, Mobile, Alabama, United States|CCOP - Greater Phoenix, Phoenix, Arizona, United States|Veterans Affairs Medical Center - Phoenix (Carl T. Hayden), Phoenix, Arizona, United States|Veterans Affairs Medical Center - Tucson, Tucson, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Veterans Affairs Medical Center - Little Rock (McClellan), Little Rock, Arkansas, United States|City of Hope Comprehensive Cancer Center, Duarte, California, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|Veterans Affairs Medical Center - West Los Angeles, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States|CCOP - Bay Area Tumor Institute, Oakland, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|CCOP - Santa Rosa Memorial Hospital, Santa Rosa, California, United States|David Grant Medical Center, Travis Air Force Base, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Veterans Affairs Medical Center - Denver, Denver, Colorado, United States|MBCCOP - Howard University Cancer Center, Washington, District of Columbia, United States|CCOP - Atlanta Regional, Atlanta, Georgia, United States|Dwight David Eisenhower Army Medical Center, Fort Gordon, Georgia, United States|Cancer Research Center of Hawaii, Honolulu, Hawaii, United States|Tripler Army Medical Center, Honolulu, Hawaii, United States|MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States|Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States|CCOP - Central Illinois, Decatur, Illinois, United States|Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital), Hines, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Genesis Medical Center, Davenport, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Veterans Affairs Medical Center - Wichita, Wichita, Kansas, United States|Veterans Affairs Medical Center - Lexington, Lexington, Kentucky, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|MBCCOP - LSU Medical Center, New Orleans, Louisiana, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, United States|Veterans Affairs Medical Center - Shreveport, Shreveport, Louisiana, United States|Boston Medical Center, Boston, Massachusetts, United States|St. Elizabeth's Medical Center, Boston, Massachusetts, United States|Veterans Affairs Medical Center - Boston (Jamaica Plain), Jamaica Plain, Massachusetts, United States|Veterans Affairs Medical Center - Ann Arbor, Ann Arbor, Michigan, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Veterans Affairs Medical Center - Detroit, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|CCOP - Grand Rapids, Grand Rapids, Michigan, United States|CCOP - Beaumont, Royal Oak, Michigan, United States|Providence Hospital - Southfield, Southfield, Michigan, United States|Veterans Affairs Medical Center - Biloxi, Biloxi, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Veterans Affairs Medical Center - Jackson, Jackson, Mississippi, United States|Keesler Medical Center - Keesler AFB, Keesler AFB, Mississippi, United States|Veterans Affairs Medical Center - Kansas City, Kansas City, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|St. Louis University Health Sciences Center, Saint Louis, Missouri, United States|CCOP - St. Louis-Cape Girardeau, Saint Louis, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|Veterans Affairs Medical Center - Albuquerque, Albuquerque, New Mexico, United States|MBCCOP - University of New Mexico HSC, Albuquerque, New Mexico, United States|Veterans Affairs Medical Center - Albany, Albany, New York, United States|Herbert Irving Comprehensive Cancer Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|CCOP - Southeast Cancer Control Consortium, Winston-Salem, North Carolina, United States|Veterans Affairs Medical Center - Cincinnati, Cincinnati, Ohio, United States|Barrett Cancer Center, Cincinnati, Ohio, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|CCOP - Columbus, Columbus, Ohio, United States|Veterans Affairs Medical Center - Dayton, Dayton, Ohio, United States|CCOP - Dayton, Dayton, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Veterans Affairs Medical Center - Oklahoma City, Oklahoma City, Oklahoma, United States|Veterans Affairs Medical Center - Portland, Portland, Oregon, United States|CCOP - Columbia River Program, Portland, Oregon, United States|Oregon Cancer Institute, Portland, Oregon, United States|Veterans Affairs Medical Center - Charleston, Charleston, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|University of Tennessee Cancer Institute, Memphis, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Veterans Affairs Medical Center - Houston, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Veterans Affairs Medical Center - San Antonio (Murphy), San Antonio, Texas, United States|Veterans Affairs Medical Center - Temple, Temple, Texas, United States|CCOP - Scott and White Hospital, Temple, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Veterans Affairs Medical Center - Salt Lake City, Salt Lake City, Utah, United States|CCOP - Virginia Mason Research Center, Seattle, Washington, United States|Veterans Affairs Medical Center - Seattle, Seattle, Washington, United States|CCOP - Northwest, Tacoma, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States",,https://ClinicalTrials.gov/show/NCT00026156,2.0,docetaxel,vinorelbine tartrate,1,1,False,False,docetaxel,vinorelbine tartrate,False,False,1.0,1.0,TRUE,
64,409,1794,1795,NCT02319577,GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial,,Unknown status,No Results Available,Non Small Cell Lung Cancer,Drug: oral vinorelbine|Drug: Gefitinib,"Progression-free survival (PFS) rate at 6 months|Overall survival (OS) rate at 1 year (1Y-OS), 2 years (2Y-OS), and 3 years (3Y-OS)|Response rate (RR)|Safety profile: Safety will be assessed by medical interview, physical examination, and blood collection for complete blood count on days 1 and 8 and biochemistry","IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",All,"18 Years and older   (Adult, Older Adult)",Phase 2,80,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,Genoa trial,12-Mar,15-Jun,15-Dec,18-Dec-14,,18-Dec-14,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy",,https://ClinicalTrials.gov/show/NCT02319577,2.0,oral vinorelbine,gefitinib,1,1,False,False,oral vinorelbine,gefitinib,False,False,1.0,1.0,TRUE,
68,439,1934,1935,NCT01204697,A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN),,Completed,Has Results,Non-Squamous Non-Small Cell Lung Cancer,Drug: docetaxel|Drug: erlotinib [Tarceva],Percentage of Participants Free From Disease Progression or Death at 6 Months|Progression-free Survival (PFS)|Overall Survival (OS)|Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR)|Percentage of Participants With Disease Control|Duration of Response (DoR),Hoffmann-La Roche,All,"18 Years and older   (Adult, Older Adult)",Phase 2,74,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,ML21869,10-Nov,14-Jul,14-Jul,17-Sep-10,16-Nov-15,16-Nov-15,"Avellino, Campania, Italy|Napoli, Campania, Italy|Parma, Emilia-Romagna, Italy|Aviano (PN), Friuli-Venezia Giulia, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Cremona, Lombardia, Italy|Milano, Lombardia, Italy|Monza, Lombardia, Italy|Pavia, Lombardia, Italy|Sondalo, Lombardia, Italy|Macerata, Marche, Italy|Lecce, Puglia, Italy|San Giovanni Rotondo, Puglia, Italy|Lido Di Camaiore, Toscana, Italy|Pisa, Toscana, Italy|Pontedera, Toscana, Italy|Treviso, Veneto, Italy|Vicenza, Veneto, Italy",,https://ClinicalTrials.gov/show/NCT01204697,2.0,docetaxel,erlotinib [tarceva],1,1,False,False,docetaxel,erlotinib [tarceva],False,False,1.0,1.0,TRUE,
69,446,1965,1966,NCT03126799,A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+),AvaTa,Recruiting,No Results Available,EGFR Positive Non-small Cell Lung Cancer,Drug: Erlotinib plus Bevacizumab|Drug: Erlotinib,PFS|ORR|OS,"National Cancer Center, Korea|Roche Korea co.,Ltd.",All,"19 Years and older   (Adult, Older Adult)",Phase 2,128,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,NCC-2016-0107,1-Nov-16,31-Dec-19,31-Dec-20,24-Apr-17,,18-Jun-18,"National Cancer Center, Goyang-Si, Gyeonggi-do, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT03126799,2.0,erlotinib plus bevacizumab,erlotinib,1,1,False,False,erlotinib plus bevacizumab,erlotinib,False,False,1.0,1.0,TRUE,
70,448,1970,1971,NCT00786331,Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC,,Unknown status,No Results Available,Advanced Non-Small Cell Lung Cancer,Drug: Pemetrexed|Drug: Pemetrexed plus carboplatin,To compare time to progression between the combination pemetrexed-carboplatin and pemetrexed alone in previously treated patients with locally advanced or metastatic NSCLC|To assess differences in terms of response rate between the combination pemetrexed-carboplatin and pemetrexed alone.|To assess differences in terms of duration of response between the combination pemetrexed-carboplatin and pemetrexed alone.|To assess differences in terms of toxicity between the combination pemetrexed-carboplatin and pemetrexed alone.|To assess differences in terms of survival between the combination pemetrexed-carboplatin and pemetrexed alone.,Gruppo Oncologico Italiano di Ricerca Clinica,All,"18 Years and older   (Adult, Older Adult)",Phase 2,230,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GOIRC 02/2006|EudraCT number 2006-004009-24,7-Jul,9-Jul,9-Dec,6-Nov-08,,3-Aug-09,"Azienda Ospedaliero-Universitaria Umberto I, Clinica di Oncologia Medica, Ancona, Italy|Azienda Ospedaliera Ospedali Riuniti di Bergamo, UO di Oncologia Medica, Bergamo, Italy|Azienda Istituti Ospitalieri di Cremona, UO di Oncologia Medica, Cremona, Italy|Azienda Sanitaria Ospedaliera S. Croce e Carle, UO di Oncologia Medica, Cuneo, Italy|Ospedale S. Croce, U.O. di Oncologia Medica, Fano, PU, Italy|Azienda Ospedaliera Careggi, UO di Oncologia Medica, Firenze, Italy|EO Ospedali Galliera, SC Oncologia Medica, Genova, Italy|Ospedale Versilia, UO di Oncologia Medica, Lido di Camaiore, LU, Italy|USL 6, Presidio Ospedaliero di Livorno, U.O. di Oncologia MedicaAzienda, Livorno, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori-IRST, Oncologia Medica, Meldola, FC, Italy|Istituto Nazionale Tumori, SC di Oncologia 2, Milano, Italy|Azienda Ospedaliero-Universitaria di Modena-Policlinico, U.O. di Oncologia Medica ed Ematologia, Modena, Italy|AO S. Gerardo, Nuovo Ospedale S. Gerardo-settore A, Oncologia Medica, Monza, MI, Italy|Azienda Ospedaliero-Universitaria di Parma, UOC di Oncologia Medica, Parma, Italy|Ospedale Silvestrini, S.C. di Oncologia Medica, Perugia, Italy|Arcispedale Santa Maria Nuova, UO di Oncologia Medica, Reggio Emilia, Italy|Azienda Ospedaliera S. Camillo-Forlanini, U.O. di Oncologia Medica, Roma, Italy|Ospedale SS. Annunziata, UO di Oncologia Medica, Sassari, Italy|Azienda Sanitaria Ospedaliera Molinette, U.O. di Oncologia Medica, Torino, Italy|P.O. Treviglio-Caravaggio, U.O. di Oncologia Medica, Treviglio, BG, Italy|Policlinico ""G. B. Rossi""-Borgo Roma, U.O. di Oncologia Medica Clinicizzata, Verona, Italy",,https://ClinicalTrials.gov/show/NCT00786331,2.0,pemetrexed,pemetrexed plus carboplatin,1,1,False,False,pemetrexed,pemetrexed plus carboplatin,False,False,1.0,1.0,TRUE,
